Cite
HARVARD Citation
Pujade-Lauraine, E. et al. (n.d.). Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet oncology. 18 (9), pp. 1274-1284. [Online].